Targeted delivery of nanoparticles for in vivo CAR T therapy

Strike Pharma is a Swedish biotech company developing in vivo CAR-T therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery

 

Learn more about our Technology, Pipeline and Disease indications, and see our Publications and posters.

Latest News

February 4, 2025

Per Norlén joins Strike Pharma as new CEO

September 10, 2024

Strike Pharma presents updates at CICON24

July 4, 2024

Strike Pharma granted patent to protect core technology

Latest Events

September 24, 2023

Strike Pharma presents further developments at CICON23

April 18, 2023

Strike Pharma presents latest developments at AACR 2023

May 2, 2022

Strike Pharma, Uppsala University and KTH Royal Institute of Technology present at CIMT 2022